Australia approves breakthrough cancer treatment for melanoma

Australia is making significant strides in the fight against melanoma, often referred to as the country’s national cancer due to high UV exposure.

Recently, the nation reached a landmark milestone in cancer care: the approval of neoadjuvant, or pre-surgery, combination immunotherapy.

Based on the successful NADINA trial, co-led by Professor Georgina Long, this strategy involves administering treatment before surgery rather than waiting until afterward.

This shift has been shown to reduce the risk of disease progression and death by approximately 68% for patients with high-risk Stage III melanoma.

On August 1, 2025, this breakthrough was officially listed on the Pharmaceutical Benefits Scheme (PBS), making it affordable and accessible for eligible Australians.

Alongside this, Australia has seen other major advancements, such as the 2024 PBS listing of Opdualag and the 2026 TGA approval of lifileucel, the first T-cell therapy for solid tumors.

These achievements highlight Australia’s status as a global leader in clinical research.

By bridging the gap between innovative trials and public funding through the PBS, Australia is ensuring that life-saving treatments are no longer just future possibilities, but current realities for patients battling advanced melanoma.